(Q38013289)

27 August 2017

title

Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development (English)

1 reference

27 August 2017

Apexa Bernard

1

1 reference

27 August 2017

Holly Kimko

series ordinal

2

1 reference

27 August 2017

Dinesh Mital

series ordinal

3

1 reference

27 August 2017

Italo Poggesi

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

26 May 2012

1 reference

Expert Opinion on Drug Metabolism & Toxicology

27 August 2017

published in

1 reference

27 August 2017

volume

8

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

1057-1069

1 reference

Can the pharmaceutical industry reduce attrition rates?

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Estimating the cost of new drug development: is it really 802 million dollars?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Model-based drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Concepts and challenges in quantitative pharmacology and model-based drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Predictive oncology: a review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Telomerase as a Target for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Envisioning the future of early anticancer drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Antitumor efficacy testing in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Advances in imaging mouse tumour models in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Predicting the active doses in humans from animal studies: a novel approach in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Optimal design of pharmacokinetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Theoretical concepts and the emerging role of taxanes in adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Tumor models for efficacy determination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

21 January 2018

DYNAMICS OF TUMOR GROWTH

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

A minimal model of tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.693480

10.1517/17425255.2012.693480

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference